Acrivon COO reports tax share withholding

Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a small tax-related share disposition.

Rhea-AI Filing Summary

Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a small tax-related share disposition. On the vesting of restricted stock units, 723 shares of common stock were withheld by the company at a price of $1.63 per share to cover mandatory tax withholding. After this non-market transaction, Devroe directly holds 74,585 shares of Acrivon Therapeutics common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 723 shares

Exercise Price or Tax Liability 1 txn

Insider Devroe Eric

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	723	$1.63	$1K

Holdings After Transaction: Common Stock — 74,585 shares (Direct)

Footnotes (1)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Acrivon Therapeutics (ACRV) report for Eric Devroe?

Acrivon Therapeutics reported that COO Eric Devroe had 723 common shares withheld to cover taxes when his restricted stock units vested. This was coded as a tax-withholding disposition rather than an open-market purchase or sale of ACRV shares.

Was the ACRV insider transaction by Eric Devroe an open-market sale?

No, the transaction was not an open-market sale. The 723 ACRV shares were withheld by Acrivon Therapeutics to satisfy mandatory tax withholding upon restricted stock unit vesting, a common administrative process reflected with transaction code "F" on the Form 4.

How many Acrivon Therapeutics (ACRV) shares were involved in Eric Devroe’s tax withholding?

The filing shows 723 ACRV common shares were withheld at $1.63 per share. These shares were used solely to satisfy mandatory tax obligations triggered when Devroe’s restricted stock units vested, rather than being sold in the open market to third-party buyers.

How many ACRV shares does Eric Devroe hold after this Form 4 transaction?

After the tax-withholding disposition, Eric Devroe directly owns 74,585 ACRV common shares. This post-transaction balance reflects his remaining equity position following the withholding of 723 shares to cover taxes on vested restricted stock units.

What does transaction code "F" mean in the ACRV Form 4 for Eric Devroe?

Transaction code "F" on the ACRV Form 4 indicates shares were used to pay a tax liability or exercise price. In this case, 723 shares were withheld by Acrivon Therapeutics to satisfy mandatory tax withholding when Devroe’s restricted stock units vested.

Is Eric Devroe’s ACRV ownership classified as direct or indirect after this filing?

Eric Devroe’s ACRV ownership is classified as direct after this transaction. The Form 4 shows the 74,585 shares he holds following the tax-withholding disposition are reported with a direct ownership code, without any intermediary entities noted in the ownership description.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/14/2026		F(1)		723	D	$1.63	74,585	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.